News Johnson & Johnson Buenos Aires S.E.

Equities

JNJD

ARDEUT110236

End-of-day quote Buenos Aires S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
9.95 ^USD	0.00%		-1.97%	-2.45%

02:51pm	Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer	MT
02:00pm	Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson Seeks US FDA Approval for Subcutaneous Amivantamab for Certain Patients With Non-Small Cell Lung Cancer	01:51pm	MT
Johnson & Johnson Submits Subcutaneous Amivantamab Biologics License Application to U.S. FDA for Patients with EGFR-Mutated Non-Small Cell Lung Cancer	01:00pm	CI
J&J: positive results in Sjögren's disease	12:31pm	CF
Johnson & Johnson's Potential Sjogren's Treatment Shows Improvement in Meeting Clinical Trial Endpoints	11:40am	MT
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study	06-15	PR
Johnson & Johnson Announces Late-Breaking Results Show nipocalimab Significantly Improves Sjögren's Disease Activity in A Phase 2 Study	06-15	CI
Johnson & Johnson : Findings from landmark RESONATE 2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first line chronic lymphocytic leukaemia treatment with up to 10 years follow up	06-14	PU
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
J&J: encouraging trial in relapsing multiple myeloma	06-14	CF
Johnson & Johnson : Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed duration IMBRUVICA® (ibrutinib) plus venetoclax as first line treatment for patients with chronic lymphocytic leukaemia, including those with high risk disease	06-14	PU
J&J: the promise of ibrutinib in CLL	06-14	CF
J&J: promising results for Imbruvica in leukemia	06-14	CF
Johnson & Johnson Reports Positive Long-Term Results for Talvey in Multiple Myeloma Study	06-14	MT
Johnson & Johnson Announces TALVEY® (Talquetamab-Tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma	06-14	CI
High-risk health workers can get routine Ebola vaccine, Gavi says	06-13	RE
Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager	06-13	MT
Xencor : J&J's Janssen Termintates Rights to Plamotamab	06-13	DJ
That's Stentertainment	06-13	AQ
High-risk health workers can get routine Ebola vaccine, says Gavi	06-13	RE
Johnson & Johnson : to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Press Release	06-12	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm